Press Releases

Name: Medicure Inc.
Address: 1250 Waverley Street, Winnipeg, Manitoba, R3T 6C6
Price range: unknown

Medicure To Participate In Renmark's Virtual Non-Deal Roadshow Series on Monday, February 8, 2021 February 4, 2021	Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial of AGGRASTAT® (tirofiban hydrochloride) Injection vs. Placebo for Induced Suppression of Platelets Activity in Aneurysmal Subarachnoid Hemorrhage Managem January 27, 2021	Medicure Announces Pivotal Phase 3 Trial IND Filing with FDA for Treatment of Seizures Associated with Pyridox(am)ine 5'-phosphate oxidase (PNPO) Deficiency January 7, 2021
Medicure Enters the US Online Pharmacy World with Acquisition of Marley Drug December 17, 2020	Medicure Retains Investor Relations Firm Renmark Financial Communications Inc. December 2, 2020	Medicure Announces Settlement of Patent Infringement Action November 18, 2020
Medicure Reports Financial Results for Quarter Ended September 30, 2020 November 11, 2020	Medicure Q3 2020 Results and Conference Call Dates November 5, 2020	Medicure announces an agreement with Reliance Life Sciences for the marketing rights of a cardiovascular biosimilar October 5, 2020
Medicure Announces AGGRASTAT® Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports August 24, 2020	Medicure Announces Termination of ReDSTM Pro Marketing and Distribution Agreement August 20, 2020	Medicure Reports Financial Results for Quarter Ended June 30, 2020 August 11, 2020
Medicure Q2 2020 Results and Conference Call Dates August 5, 2020	Medicure Announces Positive Results for AGGRASTAT® in the FABOLUS-FASTER Trial and Publication in the Journal - Circulation June 29, 2020	Medicure Announces Normal Course Issuer Bid June 29, 2020
Medicure Announces a Direct to Patient Online Pharmacy Program for Distribution of ZYPITAMAG (Pitavastatin) Tablets June 25, 2020	Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT® will be Presented at the PCR e-Course, Late Breaking Trial Sessions, June 27, 2020 June 15, 2020	Medicure Reports Financial Results for Quarter Ended March 31, 2020 May 12, 2020
Medicure Q1 2020 results and conference call dates May 6, 2020	Medicure Reports Financial Results for Quarter and Year Ended December 31, 2019 April 15, 2020	Medicure To Announce Fiscal Year End 2019 Financial Results on April 15, 2020 April 13, 2020
Medicure Announces the Completion of Shortened AGGRASTAT® Versus Integrilin® in Percutaneous Coronary Intervention (SAVI-PCI) Study December 20, 2019	Medicure Announces Preliminary Results of Substantial Issuer Bid December 20, 2019	Medicure Announces Completion of Enrollment for FABOLUS-FASTER, Phase 4 Clinical Trial of Aggrastat (Tirofiban Hydrochloride) Injection VS Kengreal (Cangrelor) in Patients Undergoing Percutaneous Coronary Intervention (PCI) December 12, 2019
Medicure Files Patent Infringement Action December 5, 2019	Medicure Announces Settlement of Holdback Dispute from Apicore Sale December 5, 2019	Medicure Reports Financial Results for Quarter Ended September 30, 2019 November 26, 2019
Medicure Q3 2019 Results and Conference Call Dates November 19, 2019	Medicure Announces Commencement of Substantial Issuer Bid November 13, 2019	Medicure Announces Intention to Commence Substantial Issuer Bid November 4, 2019
Medicure Announces SMILE-HF Study Demonstrates Use of ReDS Results in 58% Reduction in Hospital Readmission Rate October 15, 2019	Medicure Announces Preferred Pricing Agreement for Zypitamag with the AIDS Drug Assistance Program ("ADAP") Crisis Task Force October 3, 2019	Medicure Announces Acquisition Of Full United States Ownership Of Zypitamag September 30, 2019
Medicure Announces Launch of New and Improved ReDS PRO September 17, 2019	Medicure Announces Settlement of Patent Infringement Action August 21, 2019	Medicure Reports Financial Results for Quarter Ended June 30, 2019 August 8, 2019
Medicure Q2 2019 Results and Conference Call Dates August 2, 2019	Medicure Announces Results of 2019 Annual Meeting of Shareholders June 26, 2019	Medicure Announces Appoinment of Dr. Neil Owens as President and Chief Operating Officer June 10, 2019
Medicure Announces Renewal of its Normal Course Issuer Bid May 30, 2019	Medicure Reports Financial Results for Quarter Ended March 31, 2019 May 27, 2019	Medicure Q1 2019 Results and Conference Call Dates May 22, 2019
Medicure Appoints Ms. Manon Harvey to its Board of Directors May 15, 2019	Medicure Reports Financial Results for Quarter and Year Ended December 31, 2018 April 29, 2019	Medicure to Announce Fiscal Year End 2018 Financial Results on April 29, 2019 April 24, 2019
Medicure Provides Update on Release of Holdback Funds from Apicore Sale February 13, 2019	Medicure Announces Agreement to Market ReDS Device for Congestive Heart Failure Patients in the United States January 28, 2019	Medicure reports financial results for quarter ended September 30, 2018 November 20, 2018
Medicure Files Patent Infringement Action November 16, 2018	Medicure Q3 2018 Results and Conference Call Dates November 14, 2018	Medicure Reports Financial Results for Quarter Ended June 30, 2018 August 15, 2018
Medicure Announces FDA Approval of Acute Care Cardiovascular Drug Sodium Nitroprusside Injection August 13, 2018	Medicure Q2 2018 Results and Conference Call Dates August 8, 2018	Medicure Reports Financial Results for Quarter Ended March 31, 2018 May 23, 2018
Medicure Q1 2018 Results and Conference Call Dates May 17, 2018	Medicure Announces Normal Course Issuer Bid May 17, 2018	Medicure Reports Financial Results for Quarter and Year Ended December 31, 2017 May 1, 2018
Medicure announces availability of ZYPITAMAG (pitavastatin) in the U.S. May 1, 2018	Medicure to Announce Fiscal Year End 2017 Financial Results on April 30, 2018 April 24, 2018	Medicure Announces Further Up-Date on PREXXARTAN® March 28, 2018

Newer | Older

Press Releases

Medicure To Participate In Renmark's Virtual Non-Deal Roadshow Series on Monday, February 8, 2021

Medicure Announces Early Completion of Enrollment for iSPASM, a Phase 1/2a Exploratory Clinical Trial of AGGRASTAT® (tirofiban hydrochloride) Injection vs. Placebo for Induced Suppression of Platelets Activity in Aneurysmal Subarachnoid Hemorrhage Managem

Medicure Announces Pivotal Phase 3 Trial IND Filing with FDA for Treatment of Seizures Associated with Pyridox(am)ine 5'-phosphate oxidase (PNPO) Deficiency

Medicure Enters the US Online Pharmacy World with Acquisition of Marley Drug

Medicure Retains Investor Relations Firm Renmark Financial Communications Inc.

Medicure Announces Settlement of Patent Infringement Action

Medicure Reports Financial Results for Quarter Ended September 30, 2020

Medicure Q3 2020 Results and Conference Call Dates

Medicure announces an agreement with Reliance Life Sciences for the marketing rights of a cardiovascular biosimilar

Medicure Announces AGGRASTAT® Shows Promise in Treating Thrombotic Complications Due to COVID-19 in Early Clinical Reports

Medicure Announces Termination of ReDSTM Pro Marketing and Distribution Agreement

Medicure Reports Financial Results for Quarter Ended June 30, 2020

Medicure Q2 2020 Results and Conference Call Dates

Medicure Announces Positive Results for AGGRASTAT® in the FABOLUS-FASTER Trial and Publication in the Journal - Circulation

Medicure Announces Normal Course Issuer Bid

Medicure Announces a Direct to Patient Online Pharmacy Program for Distribution of ZYPITAMAG (Pitavastatin) Tablets

Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT® will be Presented at the PCR e-Course, Late Breaking Trial Sessions, June 27, 2020

Medicure Reports Financial Results for Quarter Ended March 31, 2020

Medicure Q1 2020 results and conference call dates

Medicure Reports Financial Results for Quarter and Year Ended December 31, 2019

Medicure To Announce Fiscal Year End 2019 Financial Results on April 15, 2020

Medicure Announces the Completion of Shortened AGGRASTAT® Versus Integrilin® in Percutaneous Coronary Intervention (SAVI-PCI) Study

Medicure Announces Preliminary Results of Substantial Issuer Bid

Medicure Announces Completion of Enrollment for FABOLUS-FASTER, Phase 4 Clinical Trial of Aggrastat (Tirofiban Hydrochloride) Injection VS Kengreal (Cangrelor) in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Medicure Files Patent Infringement Action

Medicure Announces Settlement of Holdback Dispute from Apicore Sale

Medicure Reports Financial Results for Quarter Ended September 30, 2019

Medicure Q3 2019 Results and Conference Call Dates

Medicure Announces Commencement of Substantial Issuer Bid

Medicure Announces Intention to Commence Substantial Issuer Bid

Medicure Announces SMILE-HF Study Demonstrates Use of ReDS Results in 58% Reduction in Hospital Readmission Rate

Medicure Announces Preferred Pricing Agreement for Zypitamag with the AIDS Drug Assistance Program ("ADAP") Crisis Task Force

Medicure Announces Acquisition Of Full United States Ownership Of Zypitamag

Medicure Announces Launch of New and Improved ReDS PRO

Medicure Announces Settlement of Patent Infringement Action

Medicure Reports Financial Results for Quarter Ended June 30, 2019

Medicure Q2 2019 Results and Conference Call Dates

Medicure Announces Results of 2019 Annual Meeting of Shareholders

Medicure Announces Appoinment of Dr. Neil Owens as President and Chief Operating Officer

Medicure Announces Renewal of its Normal Course Issuer Bid

Medicure Reports Financial Results for Quarter Ended March 31, 2019

Medicure Q1 2019 Results and Conference Call Dates

Medicure Appoints Ms. Manon Harvey to its Board of Directors

Medicure Reports Financial Results for Quarter and Year Ended December 31, 2018

Medicure to Announce Fiscal Year End 2018 Financial Results on April 29, 2019

Medicure Provides Update on Release of Holdback Funds from Apicore Sale

Medicure Announces Agreement to Market ReDS Device for Congestive Heart Failure Patients in the United States

Medicure reports financial results for quarter ended September 30, 2018

Medicure Files Patent Infringement Action

Medicure Q3 2018 Results and Conference Call Dates

Medicure Reports Financial Results for Quarter Ended June 30, 2018

Medicure Announces FDA Approval of Acute Care Cardiovascular Drug Sodium Nitroprusside Injection

Medicure Q2 2018 Results and Conference Call Dates

Medicure Reports Financial Results for Quarter Ended March 31, 2018

Medicure Q1 2018 Results and Conference Call Dates

Medicure Announces Normal Course Issuer Bid

Medicure Reports Financial Results for Quarter and Year Ended December 31, 2017

Medicure announces availability of ZYPITAMAG (pitavastatin) in the U.S.

Medicure to Announce Fiscal Year End 2017 Financial Results on April 30, 2018

Medicure Announces Further Up-Date on PREXXARTAN®

Stay Connected

Sign up for our newsletter

About

MC-1 for PNPO Deficiency

Products

Newsroom

Investors

Contact Us

Medicure Announces a Direct to Patient Online Pharmacy Program for Distribution of ZYPITAMAG (Pitavastatin) Tablets

Medicure Announces SMILE-HF Study Demonstrates Use of ReDS Results in 58% Reduction in Hospital Readmission Rate

Medicure Announces Preferred Pricing Agreement for Zypitamag with the AIDS Drug Assistance Program ("ADAP") Crisis Task Force

Medicure Announces Acquisition Of Full United States Ownership Of Zypitamag

Medicure Announces Launch of New and Improved ReDS PRO

Medicure Announces Agreement to Market ReDS Device for Congestive Heart Failure Patients in the United States

Medicure announces availability of ZYPITAMAG (pitavastatin) in the U.S.